U.S. clinical-stage biotechnology company Kaleido Biosciences has registered with the Securities and Exchange Commission to secure up to $100 million in an initial public offering (IPO).

Kaleido Biosciences intends to list on the Nasdaq under the symbol KLDO.

The joint bookrunners on the offering include Goldman Sachs, J.P. Morgan and Morgan Stanley.

Kaleido BioSciences has bagged a total of $165.5 million in over 3 funding rounds.